Abbott’s medical device sales were down about 20% year-over-year in the second quarter of 2020, but diagnostics sales were up 7%. Procedure trends at the end of the second quarter suggest that demand for devices will soon recover to pre-pandemic levels.
Demand for Abbott Laboratories’ medical devices is beginning to recover, following the rapid contraction in sales caused by the COVID-19 pandemic in the first half of 2020.
In March and April, hospitals around the world shifted their available resources to treat COVID-19 patients and postponed or cancelled...
Joshi joins the parent company of Citeline, home of Medtech Insight, to focus on AI, business harmonization and long-term growth.
A revised annex to the original decision also outlines expert remuneration limits and introduces further changes.
CMS is proposing to classify all CGMs and insulin pumps as “items requiring frequent and substantial servicing” to expand device choice and access for Medicare beneficiaries. Under this framework, CMS also intends to move Class II devices, which include CGMs from Abbott and Dexcom and pumps from Tan
